Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Beyond Hydroxyurea: New and Old Drugs in the Pipeline for Sickle Cell Disease
authors: Telen MJsummary/abstract:
Despite Food and Drug Administration (FDA) approval of hydroxyurea to reduce the frequency of vaso-occlusive episodes, sickle cell disease (SCD) has continued to be treated primarily with analgesics for pain relief. However, elucidation of the multiple pathophysiologic mechanisms leading to vaso-occlusion and tissue injury in SCD has now resulted in a burgeoning effort to identify new treatment modalities to prevent or ameliorate the consequences of the disease. Development of new drugs as well as investigation of drugs previously used in other settings have targeted cell adhesion, inflammatory pathways, upregulation of hemoglobin F, hemoglobin polymerization and sickling, coagulation, and platelet activation. Although these efforts have not yet yielded drugs ready for FDA approval, several early studies have been extremely encouraging. Moreover, the marked increase in clinical pharmaceutical research addressing SCD and the new and old drugs in the pipeline make it reasonable to expect that we will soon have new treatments for SCD.organization: Division of Hematology, Department of Medicine, and Duke Comprehensive Sickle Cell Center, Duke University, Durham, NC, USA
read more full text
ADDMEDICA receives FDA-approval for orphan drug Siklos®, first and sole hydroxyurea-based treatment for paediatric ...ADDMEDICA has announced that the...
La Jolla Pharmaceutical company announces initiation of pivotal clinical study of LJPC-401 in patients with beta tha...La Jolla Pharmaceutical company today an...
Genetic Treatments for Sickle CellFor decades physicians have known that a...
What is a bone marrow stem cell transplant?http://www.sicklecelltransplantconsortiu...
Optimizing Hydroxyurea Therapy for Sickle Cell AnemiaHydroxyurea has proven efficacy in numer...
Sickle Cell Anemia Explanationhttps://www.youtube.com/watch?v=3ar56G4N...
Partnership to Ensure Supply of LentiGlobin, Potential Gene TherapyBluebird Bio extended a partnership with...
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.